[go: up one dir, main page]

EA200901397A1 - METHOD FOR SELECTING A PATIENT WITH A DISEASE SUFFICIENTLY TREATED BY AN APOPTICAL AGENT - Google Patents

METHOD FOR SELECTING A PATIENT WITH A DISEASE SUFFICIENTLY TREATED BY AN APOPTICAL AGENT

Info

Publication number
EA200901397A1
EA200901397A1 EA200901397A EA200901397A EA200901397A1 EA 200901397 A1 EA200901397 A1 EA 200901397A1 EA 200901397 A EA200901397 A EA 200901397A EA 200901397 A EA200901397 A EA 200901397A EA 200901397 A1 EA200901397 A1 EA 200901397A1
Authority
EA
Eurasian Patent Office
Prior art keywords
agent
apoptical
patient
selecting
sufficiently treated
Prior art date
Application number
EA200901397A
Other languages
Russian (ru)
Inventor
Шрирам Баласубраманьян
Джозеф Дж. Багги
Джейсон Рамос
Минт Сирисавад
Original Assignee
Фармасайкликс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/779,743 external-priority patent/US7820711B2/en
Application filed by Фармасайкликс, Инк. filed Critical Фармасайкликс, Инк.
Publication of EA200901397A1 publication Critical patent/EA200901397A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Inorganic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)

Abstract

Описаны способы использования потока кальция в качестве биомаркера для отбора и определения пациентов, которые способны реагировать на апоптический агент как терапевтическое средство. Также описаны способы использования потока кальция в качестве клинического биомаркера для определения чувствительности опухоли к ингибитору HDAC.Methods are described for using calcium flux as a biomarker to select and identify patients who are able to respond to an apoptotic agent as a therapeutic agent. Methods for using calcium flux as a clinical biomarker to determine tumor sensitivity to an HDAC inhibitor are also described.

EA200901397A 2007-04-13 2008-04-11 METHOD FOR SELECTING A PATIENT WITH A DISEASE SUFFICIENTLY TREATED BY AN APOPTICAL AGENT EA200901397A1 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US91185707P 2007-04-13 2007-04-13
US94440907P 2007-06-15 2007-06-15
US11/779,743 US7820711B2 (en) 2006-11-14 2007-07-18 Uses of selective inhibitors of HDAC8 for treatment of T-cell proliferative disorders
US95477707P 2007-08-08 2007-08-08
US2602308P 2008-02-04 2008-02-04
PCT/US2008/060098 WO2008128093A1 (en) 2007-04-13 2008-04-11 Calcium flux as a pharmacoefficacy biomarker for inhibitors of histone deacetylase

Publications (1)

Publication Number Publication Date
EA200901397A1 true EA200901397A1 (en) 2010-04-30

Family

ID=39864341

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200901397A EA200901397A1 (en) 2007-04-13 2008-04-11 METHOD FOR SELECTING A PATIENT WITH A DISEASE SUFFICIENTLY TREATED BY AN APOPTICAL AGENT

Country Status (8)

Country Link
EP (1) EP2144622A4 (en)
JP (1) JP2010526280A (en)
KR (1) KR20100016524A (en)
CN (1) CN101678081A (en)
AU (1) AU2008240209A1 (en)
CA (1) CA2683822A1 (en)
EA (1) EA200901397A1 (en)
WO (1) WO2008128093A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104081203B (en) 2011-07-08 2018-07-31 索隆-基特林癌症研究协会 Uses of labeled HSP90 inhibitors
CN103310105A (en) * 2013-06-13 2013-09-18 浙江加州国际纳米技术研究院绍兴分院 Method for screening non-small-cell lung cancer curative effect biomarker

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7416893B2 (en) * 2002-12-06 2008-08-26 Atto Bioscience Methods for diagnosing drug-resistant cancer cells or for identifying chemotherapeutic agents by measuring anomalous intracellular ion and/or second messenger dynamics
JP2008532515A (en) * 2005-03-10 2008-08-21 エイジェンシー フォオ サイエンス，テクノロジー アンド リサーチ A method to assess the suitability of cancer patients for treatment with histone deacetylase inhibitors

Also Published As

Publication number Publication date
JP2010526280A (en) 2010-07-29
EP2144622A1 (en) 2010-01-20
WO2008128093A1 (en) 2008-10-23
CA2683822A1 (en) 2008-10-23
CN101678081A (en) 2010-03-24
EP2144622A4 (en) 2010-06-09
AU2008240209A1 (en) 2008-10-23
KR20100016524A (en) 2010-02-12

Similar Documents

Publication Publication Date Title
EA201490230A1 (en) USE OF SWINDLE HSP90 INHIBITORS
WO2010017515A3 (en) Breast cancer specific markers and methods of use
EA201071099A1 (en) SALT FORMS OF THE mTOR INHIBITOR
WO2013022953A3 (en) Biomarker for alzheimer's disease and/or mild cognitively impairment, and use thereof
WO2010091049A3 (en) Diagnosis and treatment of cancer
CY1118566T1 (en) DIAGNOSIS USING INTERFERENCE TYPE 1
NZ609493A (en) Diagnosis and treatments relating to th2 inhibition
EA201290988A1 (en) STEREELECTIVE SYNTHESIS OF PHOSPHORUS-CONTAINING ACTIVE COMPOUNDS
EA200900177A1 (en) SUBSTITUTED ACYLANILIDES AND METHODS OF THEIR APPLICATION
CY1116089T1 (en) CD73 AS A INDICATOR FOR MONITORING DISEASE DEVELOPMENT AND TREATMENT OF TREATMENT EFFICIENCY
EA201100923A1 (en) HUMAN ANTIBODIES AGAINST THE TISSUE FACTOR
EA201390150A1 (en) METHODS OF IDENTIFYING SIGNATURES OF DISEASE OR PATHOLOGICAL CONDITIONS IN THE FLOWS OF THE ORGANISM
WO2012006589A3 (en) Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling
EA201300558A1 (en) CONNECTIONS AND METHODS FOR MORNING PAIN
EA201101568A1 (en) TREATMENT OF EX VIVO IMMUNOLOGICAL DISORDERS THROUGH PKC-TETA INHIBITORS
ES2570632T3 (en) In vitro leukocyte elastase inhibitor determination procedure for colorectal cancer
IN2012DN06309A (en)
MX382266B (en) METHOD FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF BREAST CANCER METASTASIS.
WO2011015602A3 (en) Lung cancer biomarkers
ES2570631T3 (en) Apolipoprotein AII determination procedure for in vitro diagnosis of colorectal cancer
WO2012078623A3 (en) Biomarkers for monitoring treatment of neuropsychiatric diseases
EP2175722A4 (en) PATIENT SELECTION AND THERAPEUTIC METHODS USING PROSTAGLANDIN METABOLISM MARKERS
CY1119653T1 (en) METHOD FOR IDENTIFYING A PATIENT'S SENSITIVITY IN TERMINATIVE SUSPENSION THERAPY
EA201190312A1 (en) SUBSTITUTED PIPERIDINES
MY179250A (en) Protein biomarkers for soft tissue disease diagnosis and as therapeutic targets for oral care intervention